Table 2

Characterisation of demographic and clinical variables in patients with SpA with HLA-B27 and HLA-B15

VariableHLA-B15 (n=34)HLA-B27 (n=70)P value
Age (years) median±SD35.7±10.035.8±13.60.97
Age of onset (years) median±SD28.2±9.427.7±10.50.81
Duration disease (years) median (IQR)3.4 (2–12)3.6 (1–12)0.86
Gender—M/F (%)15/19 (44/56)55/15 (79/21)<0.001
Ratio—M:F0.8:13.7:1
 ESSG criteria
  AS (n=54)13410.08
  uSpA (n=32)17150.006
  ReA (n=18)4140.44
 ASAS criteria
 axSpA
  Patients with axSpA (n=97)2770<0.001
  Patients with pure axSpA (n=10)0100.05
  Patients with mixed ax/pSpA (n=87)27600.6
 pSpA
  Patients with pSpA (n=94)3460
  Patients with pure pSpA (n=4)400.029
  Patients with mixed ax/pSpA (n=90)3060
  • AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; axSpA, axial SpA; ESSG, European Spondyloarthropathy Study Group; HLA, human leukocyte antigen; pSpA, peripheral SpA; ReA, reactive spondyloarthritis; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.